SCHOLARLY PUBLICATION

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

📖 The Lancet Oncology → 📅 2009-03-10 🔗 DOI: 10.1016/s1470-2045(09)70025-7

View Journal Profile → View Official Paper ↗

📄 Abstract

The abstract has not yet been added. Use the official source link for the complete publication record.

ℹ️ Publication Details

Journal: The Lancet Oncology
Published: 2009-03-10
DOI: 10.1016/s1470-2045(09)70025-7
OpenAlex: W2158681922
Access: Via publisher

📋 Cite This Paper

Roger Stupp, Monika E. Hegi, Warren P. Mason, Martin J. van den Bent, Martin Taphoorn, Robert Charles Janzer, Samuel K. Ludwin, Anouk Allgeier, Barbara Fisher, Karl Bélanger, Peter Hau, Alba Ariela Brandes, Johanna M. M. Gijtenbeek, Christine Marosi, Charles J. Vecht, Karima Mokhtari, Pieter Wesseling, S. Villà, Elizabeth A. Eisenhauer, Thierry Gorlia, Michael Weller, Denis Lacombe, John Gregory Cairncross, René‐Olivier Mirimanoff (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(09)70025-7

📄 Abstract

🔬 Related Research Papers

De-novo and acquired resistance to immune checkpoint targeting

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Increasing incidence of colorectal cancer in Asia: implications for screening

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial